• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    US Gene Editing Market

    ID: MRFR/LS/11815-HCR
    100 Pages
    Garvit Vyas
    September 2025

    US Gene Editing Market Research Report: By Technology (CRISPR, TALEN, ZFN, Antisense, others), By Application (Genetic Engineering, Gene Therapy, Cell Line Engineering, Others), By Method (Ex-vivo, In-vivo) and By End User (Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), Academic & Government Research Institutes) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Gene Editing Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    US Gene Editing Market Summary

    The United States gene editing market is poised for substantial growth, projected to reach 18 USD billion by 2035.

    Key Market Trends & Highlights

    US Gene Editing Key Trends and Highlights

    • The market valuation is estimated at 2.5 USD billion in 2024, indicating a robust starting point for growth.
    • From 2025 to 2035, the market is expected to grow at a compound annual growth rate of 19.66 percent.
    • By 2035, the gene editing market in the United States is anticipated to expand to 18 USD billion, reflecting increasing demand.
    • Growing adoption of gene editing technologies due to advancements in research and development is a major market driver.

    Market Size & Forecast

    2024 Market Size 2.5 (USD Billion)
    2035 Market Size 18 (USD Billion)
    CAGR (2025-2035) 19.66%

    Major Players

    Editas Medicine, Cellectis, Amgen, Novartis, Bluebird Bio, Sangamo Therapeutics, Thermo Fisher Scientific, Inovio Pharmaceuticals, Illumina, CRISPR Therapeutics, Intellia Therapeutics, Precision BioSciences, Applied StemCell, Regeneron Pharmaceuticals, Vertex Pharmaceuticals

    US Gene Editing Market Trends

    The US Gene Editing Market is witnessing significant advancements driven by several key market drivers. One major driver is the increasing investment in research and development from both government and private sectors, aimed at harnessing gene editing technologies for therapeutic applications.

    The National Institutes of Health and the Department of Agriculture in the US have been supporting various gene editing projects, focusing on areas like agriculture and healthcare.

    Additionally, the rising prevalence of genetic disorders and the demand for personalized medicine are fueling the growth of gene editing applications. Opportunities to be explored in the US include the development of CRISPR-associated therapies that can provide efficient solutions for conditions such as sickle cell disease and certain cancers.

    The agricultural sector also presents substantial market opportunities, particularly in crop enhancement and food security, aligning with the US government's interests in sustainable agricultural practices.

    Moreover, with increased collaboration between biotech firms and academic institutions, various innovative applications of gene editing are emerging that can advance areas such as regenerative medicine. Trends in recent times indicate a push for regulatory clarity surrounding gene editing techniques, as organizations like the FDA and USDA work to outline guidelines for the safe use of these technologies.

    Public engagement and education regarding gene editing's benefits and ethical considerations are becoming increasingly relevant, as discussions about gene safety and biodiversity gain attention in the US.

    Additionally, the ongoing development of more precise, effective, and ethical gene editing methods continues to shape the market landscape, allowing for broader acceptance within both scientific and public communities.

    Overall, the US Gene Editing Market is positioned for growth, with a focus on addressing health challenges and agricultural needs through innovative gene editing solutions.

    US Gene Editing Market Drivers

    Market Segment Insights

    Gene Editing Market Technology Insights

    The US Gene Editing Market has seen substantial advancements in the Technology segment, particularly with the emergence of various methodologies that are pivotal in driving innovation and research. Within this landscape, CRISPR technology stands out for its simplicity and efficiency, enabling precise gene modification with minimal off-target effects.

    Its widespread application in biotechnology, agriculture, and healthcare has made it a cornerstone of gene editing efforts in the US.

    Meanwhile, TALEN (Transcription Activator-Like Effector Nucleases) technology offers the advantage of creating custom nucleases for specific DNA sequences, thereby facilitating targeted gene edits with robust applications in therapeutics and crop enhancement.

    ZFN (Zinc Finger Nucleases) serves as another critical technology, allowing for the targeting of specific DNA sequences for alterations, commonly used in gene therapy and genetic engineering. Although it is more complex compared to CRISPR, its capabilities in generating knockout models have positioned it as a valuable tool in biological research.

    Antisense technology, which employs short nucleic acid sequences to bind to mRNA, is extensively utilized in developing therapies that can silence specific genes, thus showing potential in treating various genetic disorders and cancers. The continued growth in the field of synthetic biology and increased funding in innovative biotechnologies support the expansion of these technologies.

    Gene Editing Market Application Insights

    The Application segment of the US Gene Editing Market encompasses various critical areas such as Genetic Engineering, Gene Therapy, Cell Line Engineering, and others, each playing a pivotal role within the industry.

    Genetic Engineering has transformed agricultural practices by enhancing crop quality and resistance to environmental stresses, addressing food security challenges in the United States.

    Meanwhile, Gene Therapy continues to gain traction as a promising method for treating genetic disorders, significantly influencing patient care and outcomes.

    Cell Line Engineering is crucial for pharmaceutical development, providing a platform for producing more effective therapies and vaccines. As the US government accelerates Research and Development initiatives in biotechnology, opportunities for these applications are expanding, bolstered by rising investments and advances in technology.

    The growing demand for personalized medicine and effective treatments further drives the evolution of the US Gene Editing Market. However, regulatory challenges and ethical considerations still pose hurdles to the widespread adoption of these applications.

    Gene Editing Market Method Insights

    The US Gene Editing Market focused on method segmentation is witnessing robust growth, driven by the increasing applications of gene editing technologies across various fields such as healthcare, agriculture, and biotech.

    The methods utilized in this market include Ex-vivo and In-vivo techniques. Ex-vivo methods are critical as they allow for the modification of cells outside the patient's body before being reintroduced, offering significant advantages in treating genetic disorders and ensuring safety.

    This approach facilitates precise targeting and high levels of customization tailored to individual patient needs. In contrast, In-vivo methods involve the direct introduction of gene editing tools into the patient's body, making them essential for real-time applications in gene therapy and regenerative medicine.

    These techniques are gaining traction due to technological advancements and the growing prevalence of chronic diseases that demand innovative treatment solutions.

    The ongoing research is addressing challenges in both delivery mechanisms and efficiency, unlocking new opportunities for stakeholders within the US Gene Editing Market industry. Consequently, the method segmentation showcases a promising landscape ripe for innovations, enhanced capabilities, and impactful applications that contribute to the healthcare and biotechnology sectors.

    Gene Editing Market End User Insights

    The End User segment of the US Gene Editing Market is characterized by a diverse array of participants, primarily including Biotechnology and Pharmaceutical Companies, Contract Research Organizations, and Academic and Government Research Institutes.

    These entities play significant roles in advancing gene editing technologies and their applications across various therapeutic areas.

    Biotechnology and Pharmaceutical Companies are critical as they spearhead innovative therapies that leverage gene editing to address genetic disorders and other diseases, thus driving substantial market growth.

    Contract Research Organizations provide essential services that accelerate the research and development process, allowing for efficient study designs and regulatory compliance.

    Meanwhile, Academic and Government Research Institutes contribute foundational knowledge and breakthroughs, often collaborating with industry players to develop cut-ting-edge applications.

    Get more detailed insights about US Gene Editing Market

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The US Gene Editing Market is characterized by rapid advancements and intense competition among biotechnology firms that are pioneering innovative technologies for gene manipulation. This market has garnered significant attention due to its potential applications in treating genetic diseases, advancing agricultural practices, and enhancing biopharmaceutical developments.

    The competitive landscape is shaped by a mix of established companies and emerging startups, each vying for technological superiority and market share. The ongoing research and development activities coupled with strategic collaborations, partnerships, and investments have intensified the competition, leading to a dynamic environment where companies are continuously seeking to outperform their rivals through novel solutions and products.

    Editas Medicine

    Editas Medicine has carved out a significant position within the US Gene Editing Market through its focus on CRISPR technology. The company has developed a strong portfolio of gene editing therapies aimed at treating genetic disorders, particularly in the realms of ophthalmology and hematology. Editas Medicine's strengths lie in its proprietary technologies and robust intellectual property position, which provide a competitive edge in the development of transformative therapies.

    The company has also established numerous partnerships with academic institutions and pharmaceutical firms, facilitating access to additional resources and expertise that enhance its research capabilities. Its commitment to advancing its pipeline of therapies combined with a clear regulatory strategy allows it to maintain an influential role in the evolving gene editing landscape.

    Cellectis

    Cellectis operates in the US Gene Editing Market with a strong emphasis on gene editing solutions that harness the power of its TALEN technology. Cellectis has developed several key products that cater to the biopharmaceutical sector, particularly in the development of CAR T-cell therapies for oncology, showcasing its expertise in transforming patient treatment options.

    The company's strategic focus on building robust collaborations, particularly within the gene and cell therapy sectors, has bolstered its market presence. Cellectis has pursued mergers and acquisitions to enhance its capabilities and expand its technology platform, exemplifying its ambition to be a leader in the competitive gene editing arena.

    With a solid pipeline and a keen focus on innovative therapeutic approaches, Cellectis is positioned to leverage its advancements to capture significant market share in the US gene editing sector.

    Key Companies in the US Gene Editing Market market include

    Industry Developments

    The US Gene Editing Market has witnessed significant developments, including increased research in CRISPR technology and advancements in personalized medicine. Companies such as Editas Medicine and CRISPR Therapeutics are leading efforts to leverage gene editing for therapeutic applications, particularly in genetic disorders and cancer treatment.

    Notably, in July 2023, Amgen acquired a small biotech firm, enhancing their gene editing capabilities and expanding their portfolio in precision medicine.

    Regulatory backing is also notable; in September 2023, the FDA approved novel gene therapies, reflecting growing confidence in gene editing as a viable treatment option. Furthermore, Illumina's partnership with the Broad Institute has catalyzed innovation in genomic sequencing, supporting the development of gene editing applications.

    The market's growth is propelled by increasing funding from government initiatives, with the National Institutes of Health allocating substantial grants for gene editing research.

    Over the past two years, companies like Vertex Pharmaceuticals and Bluebird Bio have reported successful clinical trials that promise to revolutionize treatment paradigms, ensuring that the US remains at the forefront of gene editing advancements. As of October 2023, the US gene editing market continues to expand, driven by technological innovations and strategic collaborations among key players.

    Market Segmentation

    Gene Editing Market Method Outlook

    • Ex-vivo
    • In-vivo

    Gene Editing Market End User Outlook

    • Biotechnology and Pharmaceutical Companies
    • Contract Research Organizations (CROs)
    • Academic & Government Research Institutes

    Gene Editing Market Technology Outlook

    • CRISPR
    • TALEN
    • ZFN
    • Antisense
    • others

    Gene Editing Market Application Outlook

    • Genetic Engineering
    • Gene Therapy
    • Cell Line Engineering
    • Others

    Report Scope

    Report Scope:
    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 1.73(USD Billion)
    MARKET SIZE 2024 2.5(USD Billion)
    MARKET SIZE 2035 18.0(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 19.657% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Editas Medicine, Cellectis, Amgen, Novartis, Bluebird Bio, Sangamo Therapeutics, Thermo Fisher Scientific, Inovio Pharmaceuticals, Illumina, CRISPR Therapeutics, Intellia Therapeutics, Precision BioSciences, Applied StemCell, Regeneron Pharmaceuticals, Vertex Pharmaceuticals
    SEGMENTS COVERED Technology, Application, Method, End User
    KEY MARKET OPPORTUNITIES CRISPR technology advancements, Agricultural biotechnology applications, Therapeutics for genetic disorders, Personalized medicine developments, Growth in regenerative medicine solutions
    KEY MARKET DYNAMICS Regulatory advancements, Increasing R&D investments, Growing healthcare applications, Rising public acceptance, Competitive landscape evolution
    COUNTRIES COVERED US

    Market Highlights

    Author
    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the US Gene Editing Market in 2024?

    The US Gene Editing Market is expected to be valued at 2.5 USD Billion in 2024.

    How large is the US Gene Editing Market projected to be by 2035?

    By 2035, the US Gene Editing Market is projected to grow significantly to 18.0 USD Billion.

    What is the expected compound annual growth rate (CAGR) for the US Gene Editing Market from 2025 to 2035?

    The US Gene Editing Market is expected to witness a CAGR of 19.657 percent from 2025 to 2035.

    Which technology segment holds the largest market share in the US Gene Editing Market in 2024?

    In 2024, the CRISPR segment holds the largest market share, valued at 1.0 USD Billion.

    What is the projected market size for the TALEN technology segment by 2035?

    The TALEN technology segment is projected to reach 3.5 USD Billion by 2035.

    Who are the key players in the US Gene Editing Market?

    Key players include Editas Medicine, Cellectis, Amgen, Novartis, and Bluebird Bio among others.

    What is the expected market size for the ZFN technology segment in 2024?

    The ZFN technology segment is expected to be valued at 0.4 USD Billion in 2024.

    What are the growth drivers for the US Gene Editing Market?

    Key growth drivers include advancements in gene editing technologies and increasing applications in therapeutics.

    How is the Antisense technology segment expected to perform by 2035?

    The Antisense segment is anticipated to grow to 1.7 USD Billion by 2035.

    What challenges does the US Gene Editing Market face currently?

    The market faces challenges such as regulatory hurdles and ethical concerns surrounding gene editing applications.

    1. EXECUTIVE
    2. SUMMARY
    3. Market Overview
    4. Key Findings
    5. Market Segmentation
    6. Competitive Landscape
    7. Challenges and Opportunities
    8. Future Outlook
    9. MARKET INTRODUCTION
    10. Definition
    11. Scope of the study
    12. Research Objective
    13. Assumption
    14. Limitations
    15. RESEARCH
    16. METHODOLOGY
    17. Overview
    18. Data
    19. Mining
    20. Secondary Research
    21. Primary
    22. Research
    23. Primary Interviews and Information Gathering
    24. Process
    25. Breakdown of Primary Respondents
    26. Forecasting
    27. Model
    28. Market Size Estimation
    29. Bottom-Up
    30. Approach
    31. Top-Down Approach
    32. Data
    33. Triangulation
    34. Validation
    35. MARKET
    36. DYNAMICS
    37. Overview
    38. Drivers
    39. Restraints
    40. Opportunities
    41. MARKET FACTOR ANALYSIS
    42. Value chain Analysis
    43. Porter's
    44. Five Forces Analysis
    45. Bargaining Power of Suppliers
    46. Bargaining
    47. Power of Buyers
    48. Threat of New Entrants
    49. Threat
    50. of Substitutes
    51. Intensity of Rivalry
    52. COVID-19
    53. Impact Analysis
    54. Market Impact Analysis
    55. Regional
    56. Impact
    57. Opportunity and Threat Analysis
    58. US
    59. Gene Editing Market, BY Technology (USD Billion)
    60. CRISPR
    61. TALEN
    62. ZFN
    63. Antisense
    64. others
    65. US
    66. Gene Editing Market, BY Application (USD Billion)
    67. Genetic
    68. Engineering
    69. Gene Therapy
    70. Cell
    71. Line Engineering
    72. Others
    73. US
    74. Gene Editing Market, BY Method (USD Billion)
    75. Ex-vivo
    76. In-vivo
    77. US
    78. Gene Editing Market, BY End User (USD Billion)
    79. Biotechnology
    80. and Pharmaceutical Companies
    81. Contract Research Organizations
    82. (CROs)
    83. Academic & Government Research Institutes
    84. Competitive Landscape
    85. Overview
    86. Competitive
    87. Analysis
    88. Market share Analysis
    89. Major
    90. Growth Strategy in the Gene Editing Market
    91. Competitive
    92. Benchmarking
    93. Leading Players in Terms of Number of Developments
    94. in the Gene Editing Market
    95. Key developments and growth
    96. strategies
    97. New Product Launch/Service Deployment
    98. Merger
    99. & Acquisitions
    100. Joint Ventures
    101. Major
    102. Players Financial Matrix
    103. Sales and Operating Income
    104. Major
    105. Players R&D Expenditure. 2023
    106. Company
    107. Profiles
    108. Editas Medicine
    109. Financial
    110. Overview
    111. Products Offered
    112. Key
    113. Developments
    114. SWOT Analysis
    115. Key
    116. Strategies
    117. Cellectis
    118. Financial
    119. Overview
    120. Products Offered
    121. Key
    122. Developments
    123. SWOT Analysis
    124. Key
    125. Strategies
    126. Amgen
    127. Financial
    128. Overview
    129. Products Offered
    130. Key
    131. Developments
    132. SWOT Analysis
    133. Key
    134. Strategies
    135. Novartis
    136. Financial
    137. Overview
    138. Products Offered
    139. Key
    140. Developments
    141. SWOT Analysis
    142. Key
    143. Strategies
    144. Bluebird Bio
    145. Financial
    146. Overview
    147. Products Offered
    148. Key
    149. Developments
    150. SWOT Analysis
    151. Key
    152. Strategies
    153. Sangamo Therapeutics
    154. Financial
    155. Overview
    156. Products Offered
    157. Key
    158. Developments
    159. SWOT Analysis
    160. Key
    161. Strategies
    162. Thermo Fisher Scientific
    163. Financial
    164. Overview
    165. Products Offered
    166. Key
    167. Developments
    168. SWOT Analysis
    169. Key
    170. Strategies
    171. Inovio Pharmaceuticals
    172. Financial
    173. Overview
    174. Products Offered
    175. Key
    176. Developments
    177. SWOT Analysis
    178. Key
    179. Strategies
    180. Illumina
    181. Financial
    182. Overview
    183. Products Offered
    184. Key
    185. Developments
    186. SWOT Analysis
    187. Key
    188. Strategies
    189. CRISPR Therapeutics
    190. Financial
    191. Overview
    192. Products Offered
    193. Key
    194. Developments
    195. SWOT Analysis
    196. Key
    197. Strategies
    198. Intellia Therapeutics
    199. Financial
    200. Overview
    201. Products Offered
    202. Key
    203. Developments
    204. SWOT Analysis
    205. Key
    206. Strategies
    207. Precision BioSciences
    208. Financial
    209. Overview
    210. Products Offered
    211. Key
    212. Developments
    213. SWOT Analysis
    214. Key
    215. Strategies
    216. Applied StemCell
    217. Financial
    218. Overview
    219. Products Offered
    220. Key
    221. Developments
    222. SWOT Analysis
    223. Key
    224. Strategies
    225. Regeneron Pharmaceuticals
    226. Financial
    227. Overview
    228. Products Offered
    229. Key
    230. Developments
    231. SWOT Analysis
    232. Key
    233. Strategies
    234. Vertex Pharmaceuticals
    235. Financial
    236. Overview
    237. Products Offered
    238. Key
    239. Developments
    240. SWOT Analysis
    241. Key
    242. Strategies
    243. References
    244. Related
    245. Reports
    246. LIST
    247. OF ASSUMPTIONS
    248. US Gene Editing Market SIZE ESTIMATES
    249. & FORECAST, BY TECHNOLOGY, 2019-2035 (USD Billions)
    250. US
    251. Gene Editing Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD
    252. Billions)
    253. US Gene Editing Market SIZE ESTIMATES &
    254. FORECAST, BY METHOD, 2019-2035 (USD Billions)
    255. US Gene
    256. Editing Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    257. PRODUCT
    258. LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    259. ACQUISITION/PARTNERSHIP
    260. LIST
    261. Of figures
    262. MARKET SYNOPSIS
    263. US
    264. GENE EDITING MARKET ANALYSIS BY TECHNOLOGY
    265. US GENE EDITING
    266. MARKET ANALYSIS BY APPLICATION
    267. US GENE EDITING MARKET
    268. ANALYSIS BY METHOD
    269. US GENE EDITING MARKET ANALYSIS BY
    270. END USER
    271. KEY BUYING CRITERIA OF GENE EDITING MARKET
    272. RESEARCH
    273. PROCESS OF MRFR
    274. DRO ANALYSIS OF GENE EDITING MARKET
    275. DRIVERS
    276. IMPACT ANALYSIS: GENE EDITING MARKET
    277. RESTRAINTS IMPACT
    278. ANALYSIS: GENE EDITING MARKET
    279. SUPPLY / VALUE CHAIN: GENE
    280. EDITING MARKET
    281. GENE EDITING MARKET, BY TECHNOLOGY, 2025
    282. (% SHARE)
    283. GENE EDITING MARKET, BY TECHNOLOGY, 2019 TO
    284. (USD Billions)
    285. GENE EDITING MARKET, BY APPLICATION,
    286. (% SHARE)
    287. GENE EDITING MARKET, BY APPLICATION, 2019
    288. TO 2035 (USD Billions)
    289. GENE EDITING MARKET, BY METHOD,
    290. (% SHARE)
    291. GENE EDITING MARKET, BY METHOD, 2019 TO
    292. (USD Billions)
    293. GENE EDITING MARKET, BY END USER,
    294. (% SHARE)
    295. GENE EDITING MARKET, BY END USER, 2019
    296. TO 2035 (USD Billions)
    297. BENCHMARKING OF MAJOR COMPETITORS

    US Gene Editing Market Segmentation

     

     

     

    • Gene Editing Market By Technology (USD Billion, 2019-2035)

      • CRISPR
      • TALEN
      • ZFN
      • Antisense
      • others

     

    • Gene Editing Market By Application (USD Billion, 2019-2035)

      • Genetic Engineering
      • Gene Therapy
      • Cell Line Engineering
      • Others

     

    • Gene Editing Market By Method (USD Billion, 2019-2035)

      • Ex-vivo
      • In-vivo

     

    • Gene Editing Market By End User (USD Billion, 2019-2035)

      • Biotechnology and Pharmaceutical Companies
      • Contract Research Organizations (CROs)
      • Academic & Government Research Institutes

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027